Professor Murat Akova News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Professor murat akova. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Professor Murat Akova Today - Breaking & Trending Today

CoronaVac COVID-19 vaccine found safe and effective in interim analysis: Lancet

Updated On 2021-07-11T08:45:50+05:30
Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19.
The preliminary findings, published in The Lancet and presented at this year s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), indicate that CoronaVac induces a robust antibody response. No severe adverse events or deaths were reported among the more than 10,000 trial participants in Turkey, with most adverse events mild and occurring within 7 days of an injection. However, more research is needed to confirm vaccine efficacy in the long term, in a more diverse group of participants, and against emerging variants of concern. ....

United Kingdom , Murat Akova , Lucy Jessop , Maheshin Ramasamy , National Immunisation Office Of The Health Service , European Congress , University Of Oxford , Hacettepe University Medical School , University Of Oxford Astrazeneca , Sinovac Life Sciences , Clinical Microbiology , Infectious Diseases , Professor Murat Akova , National Immunisation Office , Health Service Executive , ஒன்றுபட்டது கிஂக்டம் , லூசி ஜெஸொப் , ஐரோப்பிய காங்கிரஸ் , பல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட் , மருத்துவ நுண்ணுயிரியல் , தொற்று நோய்கள் , தேசிய நோய்த்தடுப்பு அலுவலகம் , ஆரோக்கியம் சேவை நிர்வாகி ,

The Lancet: CoronaVac COVID-19 vaccine is safe and protects against disease, interim analysis

E-Mail
Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19.
The preliminary findings, published in The Lancet and presented at this year s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), indicate that CoronaVac induces a robust antibody response. No severe adverse events or deaths were reported among the more than 10,000 trial participants in Turkey, with most adverse events mild and occurring within 7 days of an injection. However, more research is needed to confirm vaccine efficacy in the long term, in a more diverse group of participants, and against emerging variants of concern. ....

Murat Akova , Academy Of Medical Sciences , Research Hospital , Marmara University , Kocaeli University , Hacettepe University Medical School , Karadeniz Technical University , Sinovac Life Sciences , Dicle University Yedikule Chest Diseases , Dege University , European Congress , Akdeniz University , Gaziantep University , University Of Oxford Astrazeneca , Turkish Health Institutes Association , Ankara University , Hacettepe University , Clinical Microbiology , Infectious Diseases , Professor Murat Akova , Turkish Health Institutes , Tepecik Training , Ankara Training , Suat Seren Chest Diseases , Surgery Training , City Hospital ,

AlphaGalileo > Item Display

Price:
Interim analysis from phase 3 randomised controlled trial of more than 10,000 participants aged 18-59 years in Turkey suggests efficacy of two doses of CoronaVac is 83.5% against symptomatic COVID-19.
In an immune response analysis of 1,400 participants from the vaccine and placebo groups, the vaccine induced a robust immune response in 90% (880/981) of participants.
No severe adverse events were observed, and most adverse events (90%) were mild and included fatigue, injection site pain, and aching muscles.
Further research is needed as the study involved a short follow-up period, relatively young, low-risk participants, and took place before the emergence of variants of concern.
Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19. ....

Murat Akova , European Congress , Hacettepe University Medical School , University Of Oxford Astrazeneca , Sinovac Life Sciences , Clinical Microbiology , Infectious Diseases , Professor Murat Akova , ஐரோப்பிய காங்கிரஸ் , மருத்துவ நுண்ணுயிரியல் , தொற்று நோய்கள் ,

China's CoronaVac gives 83.5% protection against Covid — Lancet study cites interim data

China’s CoronaVac gives 83.5% protection against Covid Lancet study cites interim data
Mohana Basu
© Provided by The Print
New Delhi: CoronaVac, the Covid vaccine developed by the Chinese pharma company, Sinovac Biotech, has been found to offer 83.5 per cent protection against symptomatic Covid-19 infection and 100 per cent protection against hospitalisation, according to a study published in The Lancet journal.
The interim data from a phase 3 trial of CoronaVac indicates that the vaccine induces a robust antibody response.
During the trials that involved more than 10,000 participants in Turkey, no severe adverse events or deaths were reported. Most reactions were mild such as fatigue and pain at the injection site and they occurred within seven days of an injection. ....

New Delhi , Murat Akova , Sinovac Biotech , Hacettepe University Medical School , Professor Murat Akova , Paramita Ghosh , புதியது டெல்ஹி , பரமித கோஷ் ,

CoronaVac jabs less effective against Gamma variant: Lancet

CoronaVac jabs less effective against Gamma variant: Lancet
prokerala.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prokerala.com Daily Mail and Mail on Sunday newspapers.

Murat Akova , Jose Luiz Proenca Modena , European Congress , Hacettepe University Medical School , Sinovac Life Sciences , University Of Campinas , Laboratory Of Emerging Viruses , Lancet Microbe , Professor Murat Akova , Clinical Microbiology , Infectious Diseases , ஐரோப்பிய காங்கிரஸ் , பல்கலைக்கழகம் ஆஃப் காம்பினாக்கள் , மருத்துவ நுண்ணுயிரியல் , தொற்று நோய்கள் ,